Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-25-097950
Filing Date
2025-07-23
Accepted
2025-07-23 17:01:26
Documents
56
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q vktx-20250630.htm   iXBRL 10-Q 2515415
2 EX-31.1 vktx-ex31_1.htm EX-31.1 17744
3 EX-31.2 vktx-ex31_2.htm EX-31.2 17720
4 EX-32.1 vktx-ex32_1.htm EX-32.1 13532
  Complete submission text file 0000950170-25-097950.txt   9127422

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT vktx-20250630.xsd EX-101.SCH 1028293
58 EXTRACTED XBRL INSTANCE DOCUMENT vktx-20250630_htm.xml XML 1694327
Mailing Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121
Business Address 9920 PACIFIC HEIGHTS BLVD, SUITE 350 SAN DIEGO CA 92121 858-704-4660
Viking Therapeutics, Inc. (Filer) CIK: 0001607678 (see all company filings)

EIN.: 461073877 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37355 | Film No.: 251143738
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)